Uterine sarcomas: clinical practice guidelines for diagnosis, treatment, and follow-up, by Spanish group for research on sarcomas (GEIS).

Autor:	Pérez-Fidalgo JA; Oncology and Hematology Department, INCLIVA Biomedical Research Institute, Hospital Clínico Universitario, CIBERONC Spain, Avda Blasco Ibañez 17, Valencia, 46010, Spain., Ortega E; Medical Oncology Department, Hospital Universitario Miguel Servet, Zaragoza, Spain., Ponce J; Gynecology Department, Hospital Universitario de Bellvitge. IDIBELL. Universidad de Barcelona, Barcelona, Spain., Redondo A; Medical Oncology Department, Hospital Universitario La Paz-IdiPAZ, Madrid, Spain., Sevilla I; Clinical and Translational Research in Cancer/Instituto de Investigaciones Biomédicas de Málaga (IBIMA)/Hospitales Universitarios Regional and Virgen de la Victoria de Málaga, Málaga, Spain., Valverde C; Medical Oncology Department, Vall d'Hebron University Hospital, Barcelona, Spain., Isern Verdum J; Radiotherapy Department, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain., de Alava E; Institute of Biomedicine of Sevilla (IBiS), Virgen del Rocio University Hospital /CSIC/University of Sevilla/CIBERONC, Sevilla, Spain.; Department of Normal and Pathological Cytology and Histology, School of Medicine, University of Seville, Seville, Spain., Galera López M; Medical Oncology Department, Hospital General Universitario Gregorio Marañón, Madrid, Spain., Marquina G; Department of Medical Oncology, Hospital Clinico San Carlos, Madrid, IdISSC, Spain.; Department of Medicine, School of Medicine, Complutense University (UCM), Madrid, IdISSC, Spain., Sebio A; Medical Oncology Department, Hospital de la Santa Creu i Sant Pau, Barcelona.; Universitat Autònoma de Barcelona, Barcelona, Spain.; Institut de Recerca Biomèdica Sant Pau (IIB Sant Pau), Barcelona, Spain.
Jazyk:	angličtina
Zdroj:	Therapeutic advances in medical oncology [Ther Adv Med Oncol] 2023 Mar 28; Vol. 15, pp. 17588359231157645. Date of Electronic Publication: 2023 Mar 28 (Print Publication: 2023).
DOI:	10.1177/17588359231157645
Abstrakt:	Uterine sarcomas are very infrequent and heterogeneous entities. Due to its rarity, pathological diagnosis, surgical management, and systemic treatment are challenging. Treatment decision process in these tumors should be taken in a multidisciplinary tumor board. Available evidence is low and, in many cases, based on case series or clinical trials in which these tumors have been included with other soft tissue sarcoma. In these guidelines, we have tried to summarize the most relevant evidence in the diagnosis, staging, pathological disparities, surgical management, systemic treatment, and follow-up of uterine sarcomas. Competing Interests: JA Perez Fidalgo declares receiving honoraria as speaker from Astrazeneca, MSD, Clovis, Pharmamar and GSK, as advisor from Astrazeneca, GSK, Abilify pharma, Azierta and clovis and funding for travel and/or meeting from Astrazeneca, MSD, GSK and Pharmamar. He also declares research support to his institution from GSK, Astrazeneca and Pharmamar. He also declares to be member of the executive committees of GEIS and GEICO. E Ortega declares conflict of interest with GSK, Astrazeneca, Clovis, Merck, Pharmamar and MSD for speakers bureau and from Merck and MSD for travel/meetings and fro advisory board from Eisai. J Ponce declares no conflict of interest A Redondo declares honoraria for speakers bureau from Astrazeneca, GSK, Clovis, and MSD. He also has received payment for advisory boards for Astrazeneca, GSK, Clovis, MSD and Boehringer and travel/meeting expenses from Astrazeneca and Clovis. I Sevilla declares payment for speakers bureaus from AAA, Novartis, Pharmamar, Ipsen, Pfizer, Amgen and Bayer. Support for travel/meetings from AAA, Novartis, Pharmamar, Ipsen, Boehringer, Advanz Pharma, Esteve Pharmaceuticals, Amgen and Bayer. Honoraria for participating in Advisory boards from AAA, Novartis, Pharmamar, Ipsen, Boehringer, Advanz Pharma, Esteve Pharmaceuticals, Amgen and Bayer. She also declares being member of the GEIS and GETNE executive committees. C Valverde declares honoraria for consulting or advisory boards from Pharmamar, Boehringer, Bayer, Deciphera and Philogen. Support for travel/meetings from Pharmamar, Boehringer and Bayer and Research funding grants to her institution from Pharmamar, Boehringer, Baryer, Deciphera, Philogen, Novartis and Pfizer. She declares to be member and president of the Group GEIS. J Isern deckares a Grant contract from Pharmamar, and support for travel/meeting from Pharmamar. E de Alava declares consulting fees from Roche, honoraria for speakers bureaus from Lilly, Bayer and Merck and support for travel/meetings from Pharmamar and Roche. M Galera declares honoraria for speaker’s bureaus from MSD and Pharmamar and support for travel /meetings from Pharmamar, MSD and Lilly and receipt of material support from Pharmamar. G Marquina declares payment for speakers bureaus from Astrazeneca, GSK, Clovis, MSD, Medicamenta, Fundacion SEOM, Eisai, Pharmamar, Bayer, Lilly, Tropos formacion, Tactics, Fundacion investigación HM hospitales, Globalianxia, Publicidad Permanyer, Transworld editors, Outcomes 10, Claris 2 Gmbh, Pharmore. She also declares support for travel/meetings from Astrazeneca, GSK, Clovis, MSD, ESGO, SEOM, SECT,Pharmamar, Grupo de estudios oncologicos,, Meidcamenta. Participation in advisory boards from Deciphera, GSK, Azierta, Boehringer, Pfizer and Pharmamar. She also declares bo be member fo SGO scientific committee (observer), EOTTD executive committee, EORTC STBSG executive committee, and EORTC GCG young representative in ENGOT and GCIG. A Sebio declares consulting fees from pharmamar and Boehringer-Ingelheim, honororaria for speakers bureaus from Pharmamar, Eisai, Merck and Lilly and support for attending travel/meetings from Pharmamar, Eisai, Merck, Amgen, Roche, Lilly. She declares to be member of the GEIS executive committee (© The Author(s), 2023.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu